Therefore, the close interplay between SHBG levels and risk factors involved in the pathogenesis of NAFLD, obesity and MetS suggests SHBG as a potential therapeutic target in the management of these diseases [25]. This evidence concerns the gene SHBG and metabolic dysfunction-associated steatotic liver disease.